Lexicon Pharmaceuticals (LXRX) Net Income towards Common Stockholders (2010 - 2026)

Lexicon Pharmaceuticals (LXRX) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$5.3 million in Q1 2026.

• On a quarterly basis, Net Income towards Common Stockholders rose 81.51% year-over-year to -$5.3 million in Q1 2026; TTM through Mar 2026 was -$43.0 million, a 77.74% increase from a year earlier, with the FY2025 full-year figure at -$60.6 million, up 90.2% from the prior year.
• Net Income towards Common Stockholders for Q1 2026 stood at -$5.3 million, up from -$16.8 million in the prior quarter.
• Over the last five years, Net Income towards Common Stockholders for LXRX reached as high as -$4.2 million in Q2 2025 and fell as low as -$68.3 million in Q3 2024.
• Historically, Net Income towards Common Stockholders has averaged -$34.6 million across 5 years, with a median of -$31.2 million in 2022.
• Across the five-year window, Net Income towards Common Stockholders tumbled 146.74% in 2023 and surged 92.75% in 2025, its largest moves.
• Year by year, Net Income towards Common Stockholders stood at -$31.2 million in 2022, then tumbled by 67.05% to -$52.2 million in 2023, then increased by 26.14% to -$38.5 million in 2024, then soared by 56.36% to -$16.8 million in 2025, then soared by 68.5% to -$5.3 million in 2026.
• Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were -$5.3 million in Q1 2026, -$16.8 million in Q4 2025, and -$16.7 million in Q3 2025.